Moriasi Sheba Kwamboka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Moriasi Sheba Kwamboka has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Da Ae Choi
Department of Microbiology, School of Medicine, Ajou University, Suwon 16499, Korea
1 shared publication - Dae Wook Kang
Department of Microbiology, School of Medicine, Ajou University, Suwon 16499, Korea
1 shared publication - Dajung Song
Department of Microbiology, School of Medicine, Ajou University, Suwon 16499, Korea
1 shared publication - Junho Kim
Department of Microbiology, School of Medicine, Ajou University, Suwon 16499, Korea
1 shared publication - Kyu Ri Han
Department of Microbiology, School of Medicine, Ajou University, Suwon 16499, Korea
1 shared publication - Sorim Lee
Department of Microbiology, School of Medicine, Ajou University, Suwon 16499, Korea
1 shared publication
Latest Publications
- Open Access
- 24 September 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (19) , 11247
Update on Extracellular Vesicle-Based Vaccines and Therapeutics to Combat COVID-19
The COVID-19 pandemic has had a deep impact on people worldwide since late 2019 when SARS-CoV-2 was first identified in Wuhan, China. In addition to its effect on public health, it has affected humans in various aspects of life, including social, economic, cultural, and political. It is also true that researchers have made vigorous efforts to overcome COVID-19 throughout the world, but they still have a long way to go. Accordingly, innumerable therapeutics and vaccine candidates have been studied for their efficacies and have been tried clinically in a very short span of time. For example, the versatility of extracellular vesicles, which are membrane-bound particles released from all types of cells, have recently been highlighted in terms of their effectiveness, biocompatibility, and safety in the fight against COVID-19. Thus, here, we tried to explain the use of extracellular vesicles as therapeutics and for the development of vaccines against COVID-19. Along with the mechanisms and a comprehensive background of their application in trapping the coronavirus or controlling the cytokine storm, we also discuss the obstacles to the clinical use of extracellular vesicles and how these could be resolved in the future.
- 24 September 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (19) , 11247
Open AccessUpdate on Extracellular Vesicle-Based Vaccines and Therapeutics to Combat COVID-19
The COVID-19 pandemic has had a deep impact on people worldwide since late 2019 when SARS-CoV-2 was first identified in Wuhan, China. In addition to its effect on public health, it has affected humans in various aspects of life, including social, economic, cultural, and political. It is also true that researchers have made vigorous efforts to overcome COVID-19 throughout the world, but they still have a long way to go. Accordingly, innumerable therapeutics and vaccine candidates have been studied for their efficacies and have been tried clinically in a very short span of time. For example, the versatility of extracellular vesicles, which are membrane-bound particles released from all types of cells, have recently been highlighted in terms of their effectiveness, biocompatibility, and safety in the fight against COVID-19. Thus, here, we tried to explain the use of extracellular vesicles as therapeutics and for the development of vaccines against COVID-19. Along with the mechanisms and a comprehensive background of their application in trapping the coronavirus or controlling the cytokine storm, we also discuss the obstacles to the clinical use of extracellular vesicles and how these could be resolved in the future.